Lys227

Site Information
VIPELNGkLtGMAFr SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 461582
Available spectra: 4 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 19 , 20 , 21 , 22 , 23 , 24 ) , mutation of modification site ( 18 )
Disease tissue studied:	colorectal cancer ( 20 , 21 ) , colorectal carcinoma ( 20 , 21 ) , gastric cancer ( 14 ) , leukemia ( 19 ) , chronic myelogenous leukemia ( 19 ) , lung cancer ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , non-small cell lung cancer ( 2 , 3 , 4 , 7 , 8 , 9 , 12 , 13 , 15 , 16 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 3 , 4 , 7 , 8 , 13 ) , non-small cell large cell lung carcinoma ( 2 , 8 ) , non-small cell squamous cell lung carcinoma ( 1 , 16 ) , small-cell lung cancer ( 5 , 6 )
Relevant cell line - cell type - tissue:	3T3 (fibroblast) ( 18 ) , A549 (pulmonary) ( 7 , 22 ) , Cal-12T (pulmonary) ( 3 ) , Calu-3 (pulmonary) ( 9 ) , DMS153 (pulmonary) ( 4 ) , DMS53 (pulmonary) ( 6 ) , DMS79 (pulmonary) ( 5 ) , HCC15 (pulmonary) ( 1 ) , HCC44 (pulmonary) ( 3 ) , HCC78 (pulmonary) ( 2 ) , HCC827 (pulmonary) ( 9 ) , HCT116 (intestinal) ( 20 , 21 , 23 , 24 ) , HeLa (cervical) ( 10 ) , Jurkat (T lymphocyte) ( 11 , 22 ) , K562 (erythroid) ( 19 ) , LOU-NH91 (squamous) ( 1 ) , lung ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 ) , MKN-45 (gastric) ( 14 ) , NCI-H128 (pulmonary) ( 5 ) , NCI-H1299 (pulmonary) ( 8 ) , NCI-H1355 (pulmonary) ( 7 ) , NCI-H1417 (pulmonary) ( 5 ) , NCI-H1437 (pulmonary) ( 3 , 4 ) , NCI-H1650 (pulmonary) ( 9 ) , NCI-H1666 (pulmonary) ( 3 ) , NCI-H1703 (squamous) ( 1 , 16 ) , NCI-H1734 (pulmonary) ( 8 ) , NCI-H1781 (pulmonary) ( 2 ) , NCI-H1792 (pulmonary) ( 7 ) , NCI-H1944 (pulmonary) ( 8 ) , NCI-H1975 (pulmonary) ( 9 ) , NCI-H2073 (pulmonary) ( 1 , 4 ) , NCI-H209 (pulmonary) ( 4 , 5 ) , NCI-H2106 (pulmonary) ( 9 ) , NCI-H2228 (pulmonary) ( 2 , 13 ) , NCI-H23 (pulmonary) ( 7 ) , NCI-H2342 (pulmonary) ( 1 ) , NCI-H2405 (pulmonary) ( 3 ) , NCI-H3122 (pulmonary) ( 2 , 12 ) , NCI-H3255 (pulmonary) ( 15 ) , NCI-H358 (pulmonary) ( 8 ) , NCI-H441 (pulmonary) ( 7 ) , NCI-H446 (pulmonary) ( 6 ) , NCI-H460 (pulmonary) ( 8 ) , NCI-H524 (pulmonary) ( 5 ) , NCI-H526 (pulmonary) ( 6 ) , NCI-H661 (pulmonary) ( 2 ) , NCI-H69 (pulmonary) ( 6 ) , NCI-H82 (pulmonary) ( 6 ) , NCI-H838 (pulmonary) ( 4 )

Downstream Regulation
Effects of modification on GAPDH:	intracellular localization ( 18 )

References
1	Rikova K (2013) CST Curation Set: 20218; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
2	Rikova K (2013) CST Curation Set: 20219; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
3	Rikova K (2013) CST Curation Set: 20220; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
4	Rikova K (2013) CST Curation Set: 20221; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
5	Rikova K (2013) CST Curation Set: 20213; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
6	Rikova K (2013) CST Curation Set: 20214; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
7	Rikova K (2013) CST Curation Set: 20215; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
8	Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
9	Rikova K (2013) CST Curation Set: 20217; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Weinert BT, et al. (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. Cell Rep 4, 842-51 23954790 Curated Info
11	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
12	Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
13	Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
14	Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
15	Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
16	Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
17	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
18	Ventura M, et al. (2010) Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase is regulated by acetylation. Int J Biochem Cell Biol 42, 1672-80 20601085 Curated Info
19	Moritz A (2010) CST Curation Set: 9820; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
20	Moritz A (2010) CST Curation Set: 9796; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
21	Moritz A (2010) CST Curation Set: 9797; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
22	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info
23	Li Y (2005) CST Curation Set: 966; Year: 2005; Biosample/Treatment: cell line, HCT116/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info
24	Li Y (2005) CST Curation Set: 967; Year: 2005; Biosample/Treatment: cell line, HCT116/EGF; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine Antibody Cat#: 9441 Curated Info